Investigation of the effects of drugs effective on PI3K-AKT signaling pathway in colorectal cancer alone and in combination (original) (raw)
The Dual PI3K/mTOR Inhibitor NVP-BEZ235 Induces Tumor Regression in a Genetically Engineered Mouse Model of PIK3CA Wild-Type Colorectal Cancer
Wei Chen
PLoS ONE, 2011
View PDFchevron_right
233 Inhibition of PI3K as a potential treatment for cancer
Ana Carrera
European Journal of Cancer Supplements, 2010
View PDFchevron_right
NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations
Serena Di Cosimo
Cancer Research, 2008
View PDFchevron_right
The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer
Margaret Schwarz
Journal of Cellular Biochemistry, 2012
View PDFchevron_right
The novel dual PI3K/mTOR inhibitor NVP-BGT226 displays cytotoxic activity in both normoxic and hypoxic hepatocarcinoma cells
Ayman Alameen, Giorgio Zauli, Carolina Simioni
Oncotarget, 2015
View PDFchevron_right
Supplementary Materials, Tables 1-2, Figure Legends 1-8 from Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor
Tobi Nagel
View PDFchevron_right
PI3K/Akt and GSK-3β prevents in a differential fashion the malignant phenotype of colorectal cancer cells
José Morgado-díaz
Journal of Cancer Research and Clinical Oncology, 2010
View PDFchevron_right
Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer
Thomas Hendrickson
ACS Medicinal Chemistry Letters, 2011
View PDFchevron_right
Identification of ETP-46321, a potent and orally bioavailable PI3K α, δ inhibitor
David Cebrian
Bioorganic & Medicinal Chemistry Letters, 2012
View PDFchevron_right
The dual PI3K/mTOR inhibitor NVP-BEZ235 enhances nab-paclitaxel antitumor response in experimental gastric cancer
Margaret Schwarz
International Journal of Oncology, 2013
View PDFchevron_right
Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor
Tobi Nagel
Molecular Cancer Therapeutics, 2012
View PDFchevron_right
The synergistic anti-proliferative effect of the combination of diosmin and BEZ-235 (dactolisib) on the HCT-116 colorectal cancer cell line occurs through inhibition of the PI3K/Akt/mTOR/NF-κB axis
Rana Elmahdy
Molecular Biology Reports, 2020
View PDFchevron_right
New Potent and Selective Inhibitor of Pim-1/3 Protein Kinases Sensitizes Human Colon Carcinoma Cells to Doxorubicin
Shuguang Liang
Anti-Cancer Agents in Medicinal Chemistry, 2014
View PDFchevron_right
Synergistic antitumor effect of NVP-BEZ235 and CAPE on MDA-MB-231 breast cancer cells
Nafiseh Esmaeil
Biomedicine & Pharmacotherapy, 2017
View PDFchevron_right
IN SILICO STUDIES OF INDAZOLE PYRIDINE ANALOGS AS POTENT INHIBITORS OF AKT PROTEIN IN CANCER
Manoj Kumar
View PDFchevron_right
Carcinogenesis of PIK3CA
Tooba Anum
Hereditary Cancer in Clinical Practice, 2013
View PDFchevron_right
Farelerde AK27 Bitkisel Karışımının Ehrlich Ascites Karsinoma Üzerine Antitümorijenik Etkisi
İbrahim KiliÇ
Kafkas Universitesi Veteriner Fakultesi Dergisi
View PDFchevron_right
Cancer Therapy : Preclinical Dual Targeting of Phosphoinositide 3-Kinase and Mammalian Target of Rapamycin Using NVP-BEZ 235 as a Novel Therapeutic Approach in Human Ovarian Carcinoma
Amer Karam
2011
View PDFchevron_right
Phytochemicals and PI3K Inhibitors in Cancer-An Insight
tabassum khan
Frontiers in pharmacology, 2017
View PDFchevron_right
Activity of any class IA PI3K isoform can sustain cell proliferation and survival
Bart Vanhaesebroeck
Proceedings of the National Academy of Sciences, 2010
View PDFchevron_right
Characterization of the Activity of the PI3K/mTOR Inhibitor XL765 (SAR245409) in Tumor Models with Diverse Genetic Alterations Affecting the PI3K Pathway
Chris Buhr, Artur Plonowski
Molecular Cancer Therapeutics, 2014
View PDFchevron_right
Therapeutic Potency of PI3K Pharmacological Inhibitors of Gastrointestinal Cancer
Maliheh Moradzadeh
Middle East Journal of Digestive Diseases, 2018
View PDFchevron_right
Discovery of novel anticancer therapeutics targeting the PI3K/Akt/mTOR pathway
Pascal Furet
Future Medicinal Chemistry, 2009
View PDFchevron_right
Selective Eradication of Colon Cancer Cells Harboring PI3K and/or MAPK Pathway Mutations in 3D Culture by Combined PI3K/AKT/mTOR Pathway and MEK Inhibition
Helmut Dolznig
International Journal of Molecular Sciences
View PDFchevron_right
Nitrik Oksit Sentaz (NOS) İnhibitörlerinin Sıçanlarda Çok Düşük Frekanslı Manyetik Alanın İndüklediği Analjezi Üzerine Etkileri
Ercan Ozdemir
Genel Tip Dergisi, 2017
View PDFchevron_right
Potent Inhibitors of Phosphatidylinositol 3 (PI3) Kinase that have Antiproliferative Activity Only When Delivered as Prodrug Forms
SYAZWANI ITRI BINTI AMRAN FBME A
ChemMedChem, 2013
View PDFchevron_right